Evidence map›Paper›PMID 31530561›Full record

Trial reportBMJ (Clinical research ed.)2019

Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study.

Alexandre Loupy, Olivier Aubert, Babak J Orandi, Maarten Naesens, Yassine Bouatou, Marc Raynaud, Gillian Divard, Annette M Jackson, Denis Viglietti, Magali Giral and 19 more

Erratum issued 5 registry-linked trialsAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
In one paragraph

Trial report in BMJ (Clinical research ed.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 5 registered trials, which are not on this map. Cited by 186 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
186citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01079143 phase3completednot on this map

Prospective, Multicenter, Randomized Open Study to Evaluate the Progression of Renal Graft Fibrosis According to the Epithelial-mesenchymal Transition (EMT) in de Novo Renal Transplant Recipients Treated Either by a CNI Free Immunosuppressive Regimen With Everolimus and Enteric-coated Mycophenolate Sodium or a CNI Based Regimen With Cyclosporine and Enteric-coated Mycophenolate Sodium

TypeinterventionalSponsorNovartis PharmaceuticalsRan2009 to 2012Enrolled194ConditionsRenal Interstitial FibrosisArmsCertican®, Neoral, Myfortic, Simulect®, Corticosteroids
NCT01873157 phase2completednot on this map

Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (BORTEJECT Study)

TypeinterventionalSponsorMedical University of ViennaRan2013 to 2017Enrolled44ConditionsLate Rejection of Renal Transplant, Antibody-mediated RejectionArmsBortezomib, Placebo
NCT03474003 completednot on this map

Multicenter International Observational Study to Build and Validate Multidimensional Risk Score in the Clinical Setting of Kidney Allograft Biopsies to Predict Long-term Allograft Survival

TypeobservationalSponsorParis Translational Research Center for Organ TransplantationRan2002 to 2020Enrolled7,557ConditionsKidney TransplantationArmsNo intervention
NCT04918199 completednot on this map

Computer Based, vs Human Based Assessment of Kidney Allograft Failure Prediction and Stratification

TypeobservationalSponsorParis Translational Research Center for Organ TransplantationRan2018 to 2021Enrolled400ConditionsKidney Transplant FailureArmsComputer based assessment (iBox), Physician assessement
NCT07269275 completednot on this mapstarted 2023, after this paper: background citation

Prognostic Value of HLA Eplet Mismatches for Long-term Kidney Transplant Outcomes

TypeobservationalSponsorParis Translational Research Center for Organ TransplantationRan2023 to 2025Enrolled5,525ConditionsKidney Transplant FailureArmsNo intervention
3 · Its place in the literature

Who cites it

186 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Using Information Available at the Time of Donor Offer to Predict Kidney Transplant Survival Outcomes: A Systematic Review of Prediction Models.Transplant international : official journal of the European Society for Organ Transplantation · 2022
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Donor-Derived Cell-Free DNA (dd-cfDNA) in Kidney Transplant Recipients With Indication Biopsy-Results of a Prospective Single-Center Trial.Transplant international : official journal of the European Society for Organ Transplantation · 2023
    Trial
  6. Trial
  7. Trial
  8. Article
  9. XGBoost Outperforms Traditional Transplant Regulatory Models Based on Regression.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. New kidneys, old risks: cardiovascular challenges after transplantation.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Review
  18. Article
  19. Article
  20. Review

126 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Alexandre LoupyUniversité de Paris, INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France alexandre.loupy@inserm.fr.ORCID 0000-0003-3388-7747
Olivier AubertUniversité de Paris, INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France.
Babak J OrandiDepartment of Surgery, University of California San Francisco School of Medicine, San Francisco, CA, USA.
Maarten NaesensDepartment of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Yassine BouatouUniversité de Paris, INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France.
Marc RaynaudUniversité de Paris, INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France.
Gillian DivardUniversité de Paris, INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France.
Annette M JacksonDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Denis VigliettiUniversité de Paris, INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France.
Magali GiralDepartment of Nephrology, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Nassim KamarUniversité Paul Sabatier, INSERM, Department of Nephrology and Organ Transplantation, CHU Rangueil & Purpan, Toulouse, France.
Olivier ThaunatDepartment of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, France.
Emmanuel MorelonDepartment of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, France.
Michel DelahousseDepartment of Transplantation, Nephrology and Clinical Immunology, Foch Hospital, Suresnes, France.
Dirk KuypersDepartment of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Alexandre HertigKidney transplant department, Tenon Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Eric RondeauKidney transplant department, Tenon Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Elodie BaillyKidney transplant department, Tenon Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Farsad EskandaryDivision of Nephrology and Dialysis, Department of Medicine III, General Hospital Vienna, Vienna, Austria.
Georg BöhmigDivision of Nephrology and Dialysis, Department of Medicine III, General Hospital Vienna, Vienna, Austria.
Gaurav GuptaDivision of Nephrology, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Denis GlotzUniversité de Paris, INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France.
Christophe LegendreUniversité de Paris, INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France.
Robert A MontgomeryNew York University Langone Transplant Institute, New York, NY, USA.
Mark D StegallWilliam J. von Liebig Centre for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA.
Jean-Philippe EmpanaUniversité de Paris, INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France.
Xavier JouvenUniversité de Paris, INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France.
Dorry L SegevDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Carmen LefaucheurUniversité de Paris, INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France.

Funding

DEEP SOUTH TRANSLATIONAL RESEARCH MENTORED CAREER DEVELOPMENT PROGRAMKL2TR003097 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAAG, KENNETH G · 2019 to 2023
$5.2M
NCATS NIH HHS KL2 TR003097
6 · The paper itself

Abstract

objectiveTo develop and validate an integrative system to predict long term kidney allograft failure.

designInternational cohort study.

settingThree cohorts including kidney transplant recipients from 10 academic medical centres from Europe and the United States.

participantsDerivation cohort: 4000 consecutive kidney recipients prospectively recruited in four French centres between 2005 and 2014. Validation cohorts: 2129 kidney recipients from three centres in Europe and 1428 from three centres in North America, recruited between 2002 and 2014. Additional validation in three randomised controlled trials (NCT01079143, EudraCT 2007-003213-13, and NCT01873157).

main outcome measureAllograft failure (return to dialysis or pre-emptive retransplantation). 32 candidate prognostic factors for kidney allograft survival were assessed.

resultsAmong the 7557 kidney transplant recipients included, 1067 (14.1%) allografts failed after a median post-transplant follow-up time of 7.12 (interquartile range 3.51-8.77) years. In the derivation cohort, eight functional, histological, and immunological prognostic factors were independently associated with allograft failure and were then combined into a risk prediction score (iBox). This score showed accurate calibration and discrimination (C index 0.81, 95% confidence interval 0.79 to 0.83). The performance of the iBox was also confirmed in the validation cohorts from Europe (C index 0.81, 0.78 to 0.84) and the US (0.80, 0.76 to 0.84). The iBox system showed accuracy when assessed at different times of evaluation post-transplant, was validated in different clinical scenarios including type of immunosuppressive regimen used and response to rejection therapy, and outperformed previous risk prediction scores as well as a risk score based solely on functional parameters including estimated glomerular filtration rate and proteinuria. Finally, the accuracy of the iBox risk score in predicting long term allograft loss was confirmed in the three randomised controlled trials.

conclusionAn integrative, accurate, and readily implementable risk prediction score for kidney allograft failure has been developed, which shows generalisability across centres worldwide and common clinical scenarios. The iBox risk prediction score may help to guide monitoring of patients and further improve the design and development of a valid and early surrogate endpoint for clinical trials.

trial registrationClinicaltrials.gov NCT03474003.

Indexed as

Kidney TransplantationAdultAgedEuropeFemaleFollow-Up StudiesGraft RejectionHumansMaleMiddle AgedPostoperative PeriodPrognosisReproducibility of ResultsRisk AssessmentUnited States

Identifiers

PMID31530561
PMCPMC6746192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.